KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges (2017 - 2025)

Amneal Pharmaceuticals has reported Amortization of Deferred Charges over the past 9 years, most recently at $3.7 million for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at $3.7 million for Q4 2025, down 45.5% from a year ago — trailing twelve months through Dec 2025 was $22.4 million (down 22.91% YoY), and the annual figure for FY2025 was $22.4 million, down 22.91%.
  • Amortization of Deferred Charges for Q4 2025 was $3.7 million at Amneal Pharmaceuticals, down from $5.0 million in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for AMRX hit a ceiling of $8.0 million in Q3 2024 and a floor of $2.1 million in Q1 2023.
  • Median Amortization of Deferred Charges over the past 5 years was $2.4 million (2021), compared with a mean of $4.0 million.
  • Biggest five-year swings in Amortization of Deferred Charges: skyrocketed 240.03% in 2024 and later plummeted 45.5% in 2025.
  • Amneal Pharmaceuticals' Amortization of Deferred Charges stood at $2.3 million in 2021, then dropped by 9.61% to $2.1 million in 2022, then surged by 121.46% to $4.7 million in 2023, then soared by 46.16% to $6.8 million in 2024, then plummeted by 45.5% to $3.7 million in 2025.
  • The last three reported values for Amortization of Deferred Charges were $3.7 million (Q4 2025), $5.0 million (Q3 2025), and $6.9 million (Q2 2025) per Business Quant data.